Vaccination with tumor cells engineered to secrete interleukin 2- immunoglobulin G fusion protein induces tumor rejection

Silvia Bulfone-Paus, Horst Von Bernuth, René Rückert, Joachim Wachtlin, Daniela Ungureanu, Michael Notter, Hans Krause, Thomas Pohl, Ralf Paus, Ulrich Kunzendorf

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Here we provide proof that the injection of tumor cells engineered to secrete interleukin 2 (IL-2)-IgG chimeric proteins locally induces potent antitumor responses, which are more effective than tumour transfection with IL-2 alone. Murine plasmacytoma cells (J558L) were stably transfected with DNA coding for a human IL-2-IgG1 or a murine IL-2-IgG2b fusion protein and were injected s.c. into syngeneic BALB/c mice. Evaluation of tumor growth and rejection patterns showed that IL-2-IgG secretion by transfected J558L tumor cells induced their rejection in all animals tested, similar to the rejection of J558L cells engineered to secrete IL-2 alone, whereas treatment with parental cells was lethal. However, mice treated with IL-2-IgG-s g J558L cells (human IL-2-IgG1 and murine IL-2-IgG2b) exhibited a significantly stronger tumor immunity against a later challenge with parental J558L cells than mice treated with IL-2-secreting tumor cells.

Original languageEnglish (US)
Pages (from-to)2707-2710
Number of pages4
JournalCancer Research
Volume58
Issue number13
StatePublished - Jul 1 1998
Externally publishedYes

Fingerprint

Interleukin-2
Vaccination
Immunoglobulin G
Neoplasms
Proteins
Plasmacytoma
Transfection
Immunity
Injections
DNA
Growth

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Bulfone-Paus, S., Von Bernuth, H., Rückert, R., Wachtlin, J., Ungureanu, D., Notter, M., ... Kunzendorf, U. (1998). Vaccination with tumor cells engineered to secrete interleukin 2- immunoglobulin G fusion protein induces tumor rejection. Cancer Research, 58(13), 2707-2710.

Vaccination with tumor cells engineered to secrete interleukin 2- immunoglobulin G fusion protein induces tumor rejection. / Bulfone-Paus, Silvia; Von Bernuth, Horst; Rückert, René; Wachtlin, Joachim; Ungureanu, Daniela; Notter, Michael; Krause, Hans; Pohl, Thomas; Paus, Ralf; Kunzendorf, Ulrich.

In: Cancer Research, Vol. 58, No. 13, 01.07.1998, p. 2707-2710.

Research output: Contribution to journalArticle

Bulfone-Paus, S, Von Bernuth, H, Rückert, R, Wachtlin, J, Ungureanu, D, Notter, M, Krause, H, Pohl, T, Paus, R & Kunzendorf, U 1998, 'Vaccination with tumor cells engineered to secrete interleukin 2- immunoglobulin G fusion protein induces tumor rejection', Cancer Research, vol. 58, no. 13, pp. 2707-2710.
Bulfone-Paus S, Von Bernuth H, Rückert R, Wachtlin J, Ungureanu D, Notter M et al. Vaccination with tumor cells engineered to secrete interleukin 2- immunoglobulin G fusion protein induces tumor rejection. Cancer Research. 1998 Jul 1;58(13):2707-2710.
Bulfone-Paus, Silvia ; Von Bernuth, Horst ; Rückert, René ; Wachtlin, Joachim ; Ungureanu, Daniela ; Notter, Michael ; Krause, Hans ; Pohl, Thomas ; Paus, Ralf ; Kunzendorf, Ulrich. / Vaccination with tumor cells engineered to secrete interleukin 2- immunoglobulin G fusion protein induces tumor rejection. In: Cancer Research. 1998 ; Vol. 58, No. 13. pp. 2707-2710.
@article{82eeb45fa5bf410ba0663a1fa46a680c,
title = "Vaccination with tumor cells engineered to secrete interleukin 2- immunoglobulin G fusion protein induces tumor rejection",
abstract = "Here we provide proof that the injection of tumor cells engineered to secrete interleukin 2 (IL-2)-IgG chimeric proteins locally induces potent antitumor responses, which are more effective than tumour transfection with IL-2 alone. Murine plasmacytoma cells (J558L) were stably transfected with DNA coding for a human IL-2-IgG1 or a murine IL-2-IgG2b fusion protein and were injected s.c. into syngeneic BALB/c mice. Evaluation of tumor growth and rejection patterns showed that IL-2-IgG secretion by transfected J558L tumor cells induced their rejection in all animals tested, similar to the rejection of J558L cells engineered to secrete IL-2 alone, whereas treatment with parental cells was lethal. However, mice treated with IL-2-IgG-s g J558L cells (human IL-2-IgG1 and murine IL-2-IgG2b) exhibited a significantly stronger tumor immunity against a later challenge with parental J558L cells than mice treated with IL-2-secreting tumor cells.",
author = "Silvia Bulfone-Paus and {Von Bernuth}, Horst and Ren{\'e} R{\"u}ckert and Joachim Wachtlin and Daniela Ungureanu and Michael Notter and Hans Krause and Thomas Pohl and Ralf Paus and Ulrich Kunzendorf",
year = "1998",
month = "7",
day = "1",
language = "English (US)",
volume = "58",
pages = "2707--2710",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Vaccination with tumor cells engineered to secrete interleukin 2- immunoglobulin G fusion protein induces tumor rejection

AU - Bulfone-Paus, Silvia

AU - Von Bernuth, Horst

AU - Rückert, René

AU - Wachtlin, Joachim

AU - Ungureanu, Daniela

AU - Notter, Michael

AU - Krause, Hans

AU - Pohl, Thomas

AU - Paus, Ralf

AU - Kunzendorf, Ulrich

PY - 1998/7/1

Y1 - 1998/7/1

N2 - Here we provide proof that the injection of tumor cells engineered to secrete interleukin 2 (IL-2)-IgG chimeric proteins locally induces potent antitumor responses, which are more effective than tumour transfection with IL-2 alone. Murine plasmacytoma cells (J558L) were stably transfected with DNA coding for a human IL-2-IgG1 or a murine IL-2-IgG2b fusion protein and were injected s.c. into syngeneic BALB/c mice. Evaluation of tumor growth and rejection patterns showed that IL-2-IgG secretion by transfected J558L tumor cells induced their rejection in all animals tested, similar to the rejection of J558L cells engineered to secrete IL-2 alone, whereas treatment with parental cells was lethal. However, mice treated with IL-2-IgG-s g J558L cells (human IL-2-IgG1 and murine IL-2-IgG2b) exhibited a significantly stronger tumor immunity against a later challenge with parental J558L cells than mice treated with IL-2-secreting tumor cells.

AB - Here we provide proof that the injection of tumor cells engineered to secrete interleukin 2 (IL-2)-IgG chimeric proteins locally induces potent antitumor responses, which are more effective than tumour transfection with IL-2 alone. Murine plasmacytoma cells (J558L) were stably transfected with DNA coding for a human IL-2-IgG1 or a murine IL-2-IgG2b fusion protein and were injected s.c. into syngeneic BALB/c mice. Evaluation of tumor growth and rejection patterns showed that IL-2-IgG secretion by transfected J558L tumor cells induced their rejection in all animals tested, similar to the rejection of J558L cells engineered to secrete IL-2 alone, whereas treatment with parental cells was lethal. However, mice treated with IL-2-IgG-s g J558L cells (human IL-2-IgG1 and murine IL-2-IgG2b) exhibited a significantly stronger tumor immunity against a later challenge with parental J558L cells than mice treated with IL-2-secreting tumor cells.

UR - http://www.scopus.com/inward/record.url?scp=15644379905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15644379905&partnerID=8YFLogxK

M3 - Article

VL - 58

SP - 2707

EP - 2710

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 13

ER -